Open-labelled, single-centre investigation of safety and tolerability of multiple ascending doses of nebulised SS0331 in healthy participants followed by investigation of preliminary efficacy of nebulised SS0331 in airway-infected patients with chronic airway infections - SIS-03
Latest Information Update: 21 Jan 2026
At a glance
- Drugs Anti-infectives (Primary)
- Indications Respiration disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms SIS-03
- Sponsors SoftOx Solutions
Most Recent Events
- 21 Jan 2026 New trial record